89 completed, 15 terminated, 7 unknown, 4 recruiting. 34 Phase 4, 31 Phase 3, 22 Phase 2, 16 Phase 1, 12 Not applicable.
Follow Lisdexamfetamine Dimesylate: new trials by email Literature Review of Lisdexamfetamine Dimesylate trials Research Report on Lisdexamfetamine Dimesylate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Assess How Centanafadine Interacts With Stimulants in the Body Centanafadine, Methylphenidate, Lisdexamfetamine - ADHD | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 40 | 2026-02-05 | 2026-05-05 |
| Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder Tirzepatide, Lisdexamfetamine Dimesylate, Guided self-help cognitive behavioral therapy - Obesity and Overweight, Binge Eating Disorder | Phase 2 | Recruiting | Johns Hopkins University | 105 | 2025-09-17 | 2026-09-09 |
| To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions. Lisdexamfetamine capsule, Elvanse® (Lisdexamfetamine dimesylate capsules, hard) - Attention Deficit/Hyperactivity Disorder (ADHD) | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 48 | 2025-05-26 | 2025-08-01 |
| Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes parental training in behavior management, Lisdexamfetamine, Methylphenidate - Attention Deficit Disorder with Hyperactivity, Diabetes Mellitus, Type 1 | Phase 2 | Recruiting | Medical University of Lodz | 150 | 2024-02-05 | 2024-11-29 |
| Vyvanse in Children Aged 6 to 12 Years Lisdexamfetamine Dimesylate, Lifestyle therapy - Obesity, Childhood | Early Phase 1 | Completed | University of Minnesota | 44 | 2023-12-20 | 2026-08-10 |
| Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users Treatment as Usual plus Placebo, Treatment as Usual plus Placebo plus Contingency Management, Treatment as Usual plus lisdexamfetamine (LDX-01) - Methamphetamine Abuse, Methamphetamine-dependence | Phase 2 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 440 | 2023-12-05 | 2026-02-05 |
| Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) Lisdexamfetamine Dimesylate (Medication), Placebo - Loss-of-control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 16 | 2022-01-02 | 2026-08-06 |
| The Day-time Response Variation of (Lis)Dexamphetamine Dexamfetamine Sulfate 5 Mg Oral Tablet, Lisdexamfetamine Dimesylate, blood samples - Adhd | Completed | Amsterdam UMC, location VUmc | 16 | 2021-07-01 | 2023-05-10 | |
| FOCUS ADHD Mobile Health App for Adult ADHD Patients Psychostimulant, FOCUS ADHD App - ADHD | Not applicable | Completed | Hospital de Clinicas de Porto Alegre | 73 | 2021-05-21 | 2024-05-16 |
| The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders Lisdexamfetamine - Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder | Unknown | Aarhus University Hospital | 413 | 2021-01-19 | 2021-08-11 | |
| Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate - Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder | Completed | Nemours Children's Clinic | 70 | 2020-09-13 | 2022-12-13 | |
| A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine Methylphenidate, Lisdexamfetamine, Atomoxetine - Attention Deficit Disorder With Hyperactivity | Completed | Janssen Research & Development, LLC | 430000 | 2019-10-09 | 2025-06-25 | |
| Real World Evidence of the Efficacy and Safety of FOQUEST Methylphenidate Hydrochloride, Lisdexamfetamine Dimesylate - Attention Deficit-Hyperactivity Disorder | Phase 4 | Completed | Purdue Pharma, Canada | 257 | 2019-09-19 | 2021-09-16 |
| Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment Lisdexamfetamine Dimesylate, Placebo - Binge-Eating Disorder, Obesity | Phase 3 | Completed | Yale University | 61 | 2019-08-07 | 2025-12-17 |
| Effects of LDX on Cognitive Processes and Appetite Placebo oral tablet, Lisdexamfetamine Dimesylate - Binge Eating, Eating Behavior | Not applicable | Terminated | University of Birmingham | 22 | 2019-05-01 | 2020-11-06 |
| Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment Lisdexamfetamine Dimesylate, Cognitive-Behavioral Therapy, Combination LDX and Cognitive-Behavioral Therapy - Binge-Eating Disorder, Obesity | Phase 3 | Completed | Yale University | 141 | 2019-03-25 | 2024-10-17 |
| Stimulant Effects on Disruptive Behavior Stimulant - Attention Deficit Hyperactivity Disorder, Problem Behavior | Phase 4 | Recruiting | Matthew J O'Brien, PhD, BCBA-D | 10 | 2018-10-01 | 2025-03-17 |
| Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents Lisdexamfetamine dimesylate, Guanfacine Extended Release Oral Tablet, Placebo - ADHD | Not applicable | Completed | King's College London | 25 | 2018-10-01 | 2026-08-12 |
| Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Lisdexamfetamine Dimesylate - Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder | Phase 4 | Completed | JPM van Stralen Medicine Professional | 48 | 2018-09-26 | 2024-02-12 |
| Lisdexamfetamine for Adults With Bulimia Nervosa Lisdexamfetamine dimesylate - Bulimia Nervosa | Phase 2 | Terminated | Aaron Keshen | 23 | 2018-06-21 | 2020-11-27 |
Showing 20 of 119. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (66) · Binge-Eating Disorder (10) · Depressive Disorder, Major (7) · Obesity (6) · Cognitive Dysfunction (5) · Schizophrenia (5) · Bipolar Disorder (4) · Substance-Related Disorders (4) · Cocaine-Related Disorders (3) · Depression (3) · Primary Ovarian Insufficiency (3) · Amphetamine-Related Disorders (2) · Behavior, Addictive (2) · Brain Injuries, Traumatic (2) · Bulimia (2)
Shire (39) · New River Pharmaceuticals (6) · University of Pennsylvania (5) · Lindner Center of HOPE (4) · Massachusetts General Hospital (4) · New York State Psychiatric Institute (4) · Duke University (3) · McGill University Health Centre/Research Institute of the McGill University Health Centre (3) · University of Minnesota (3) · Yale University (3) · NYU Langone Health (2) · Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · Seattle Children's Hospital (2) · Vanderbilt University (2) · Aarhus University Hospital (1)
United States (93) · Canada (15) · Germany (11) · Sweden (9) · Spain (8) · Hungary (7) · Poland (7) · United Kingdom (7) · Belgium (5) · Italy (4) · Netherlands (3) · Romania (3) · Chile (2) · Czechia (2) · Estonia (2)
Lily Hechtman, MD, FRCPC (4) · C. Neill Epperson, MD (3) · Carlos M Grilo, Ph.D. (2) · Joseph Biederman, M.D. (2) · Joseph Biederman, MD (2) · Mark A Stein, PhD (2) · Scott H Kollins, PhD (2) · Aaron Keshen, MD, FRCPC (1) · Agnieszka Butwicka, A/Prof (1) · Alex Odermatt, Dr. (1) · Ann Childress, M.D. (1) · Ariana M Chao, PhD, CRNP, FNP-BC (1) · Carlos Grilo, PhD (1) · Claudia Fox, MD (1)
PMID 32237290, PMID 20215923, PMID 21367347, PMID 23356790, PMID 26063677, PMID 26346638, PMID 27474961, PMID 28980198, PMID 29497297, PMID 30013816, PMID 30817099, PMID 17577466, PMID 17631866, PMID 19012818, PMID 19508731, PMID 19650932, PMID 19820270, PMID 20035583, PMID 20141706, PMID 20978273, PMID 21156071, PMID 21173426, PMID 21186969, PMID 21356232, PMID 21421179, PMID 21438796, PMID 21474905, PMID 21824454, PMID 22054243, PMID 22166471, PMID 22780921, PMID 22808446, PMID 23174471, PMID 23254273, PMID 23332456, PMID 23410138, PMID 23512639, PMID 23615868, PMID 23708466, PMID 23756608, PMID 23893527, PMID 23945447, PMID 23959815, PMID 24021497, PMID 24106804, PMID 24297663, PMID 24309905, PMID 24796970, PMID 24839883, PMID 25038977
2008 (2), R01DK114075 (2), 2009 (1), P30MH066386 (1), P50DA009236 (1), R01DK126637 (1), R21DA034824 (1), U01MH093582 (1)